Premium Tolvaptan API in Pakistan: Reliable Raw Material Supply for Pharmaceutical Formulators

Product Name: Tolvaptan (Active Pharmaceutical Ingredient)

Supplier / Distributor: Morgan

Therapeutic Category: Selective Vasopressin V2-Receptor Antagonist (Aquaretic)

Indications: Hyponatremia, Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Compliance Notice: This technical data page is strictly for B2B pharmaceutical manufacturers, contract manufacturing organizations (CMOs), and analytical laboratories. The Tolvaptan distributed by Morgan is a highly purified Active Pharmaceutical Ingredient (API) intended exclusively for commercial formulation and laboratory R&D. It is not a finished drug product.

About Morgan: Morgan Chemicals (Pvt.) Ltd. is a pharmaceutical raw material trading and distribution company. We source APIs from DRAP-registered and internationally certified manufacturers and supply exclusively to licensed pharmaceutical companies, CMOs, and research facilities. We do not manufacture APIs or sell finished medicines.

Product Overview and Mechanism of Action

Tolvaptan is a highly potent, orally active, non-peptide small-molecule Active Pharmaceutical Ingredient (API). In renal and cardiovascular pharmacology, it is classified as a selective vasopressin V2-receptor antagonist, functioning primarily as an aquaretic agent.

Unlike traditional loop or thiazide diuretics that promote the excretion of sodium and potassium alongside water, Tolvaptan utilizes a fundamentally different mechanism. At the physiological level, the API competitively binds to the V2 receptors located on the basolateral membrane of the principal cells in the renal collecting ducts. By blocking arginine vasopressin (AVP)—also known as antidiuretic hormone (ADH)—from binding to these receptors, Tolvaptan inhibits the intracellular cAMP signaling cascade.

This inhibition directly prevents the translocation and insertion of aquaporin-2 (AQP2) water channels into the apical membrane. As a result, the renal collecting ducts remain impermeable to water, leading to a profound increase in free water excretion (aquaresis) without altering electrolyte excretion. This specific pharmacological action raises serum sodium concentrations, making it highly effective in treating hypervolemic and euvolemic hyponatremia. Furthermore, by blocking V2 receptors, Tolvaptan significantly slows the proliferation of renal cysts and the decline of kidney function in patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD).

For pharmaceutical formulation scientists, integrating this API allows for the development of modern, targeted aquaretic therapeutics. In finished pharmaceutical products, Tolvaptan is standardly formulated into immediate-release oral solid dosage forms ranging from 15 mg to 90 mg tablets.

Sourcing Tolvaptan in Pakistan: Morgan’s Supply Network

Developing and commercializing advanced renal and cardiovascular formulations requires a highly resilient and traceable raw material pipeline. Procuring specialty aquaretic APIs for local commercial manufacturing frequently involves navigating extended lead times, stringent customs bottlenecks, and highly complex regulatory compliance. Sourcing Tolvaptan Pakistan through Morgan’s localized distribution network mitigates these complex supply chain risks.

Morgan sources commercial-scale and pilot-scale quantities from global manufacturing partners operating in strict adherence to ICH Q7 Good Manufacturing Practice (GMP) guidelines. Partnering with Morgan as your primary supply vendor secures several operational provisions for your manufacturing facility:

• DRAP Submission Assistance: Morgan coordinates with DRAP-registered API manufacturers to obtain and forward the necessary compliance documentation on your behalf. This includes the open part of the Drug Master File (DMF), comprehensive impurity profiles (such as 5-Oxo or 4-Hydroxy impurities), and accelerated stability data to strictly support your Drug Regulatory Authority of Pakistan (DRAP) dossier submissions.
• Supply Chain Stability: Our localized API inventory management eliminates international transit variables. Whether you are conducting pilot batches or executing a high-volume Tolvaptan api Pakistan procurement order, we help ensure that your commercial batch schedules and production timelines are met without costly line stoppages.
• Batch-to-Batch Uniformity: Every shipment coordinated by Morgan includes a detailed Certificate of Analysis (CoA) issued by the original manufacturer. We ensure our supplied batches maintain consistent chemical purity, controlled moisture limits, and a precise particle size distribution (PSD) for predictable behavior during blending and direct compression.

Technical Specifications for QA & R&D

The Tolvaptan API supplied by Morgan undergoes exacting analytical testing at the source to meet current international pharmacopeial standards.

• Chemical Name: N-[4-[(7-Chloro-2,3,4,5-tetrahydro-5-hydroxy-1H-1-benzazepin-1-yl)carbonyl]-3-methylphenyl]-2-methylbenzamide
• CAS Number: 150683-30-0
• Appearance: White to off-white crystalline solid powder
• Molecular Formula: C26H25ClN2O3
• Molecular Weight: 448.94 g/mol
• Assay / Purity (HPLC): ≥ 99.0%
• Solubility Profile: Very slightly soluble in water; soluble in organic solvents such as methanol and DMSO. Detailed solubility parameters across standard solvents and aqueous buffers are documented in the technical data sheet to assist your analytical R&D teams with dissolution profiling.

Manufacturing and Handling Guidelines for Formulators

Tolvaptan is a pharmacologically active compound with specific handling requirements. Facilities processing this API must enforce strict occupational exposure limits (OEL) to protect personnel on the manufacturing floor.

• Storage Conditions: Store the raw API powder in securely closed, light-resistant containers. Maintain climate-controlled conditions as specified by the batch protocol (typically 2-8°C or controlled room temperature, strictly protected from excessive heat and ambient humidity) to prevent chemical degradation.
• Occupational Safety: Personnel handling the pure API powder must follow advanced industrial containment protocols. Processing requires appropriate Personal Protective Equipment (PPE), including P3/N95 industrial dust masks or respirators, chemical-resistant nitrile gloves, and full protective facility garments. Dispensing, milling, and compounding stages must be executed within localized exhaust ventilation systems or dedicated negative-pressure weighing booths to prevent the inhalation of airborne particulates and facility cross-contamination.

Distributor Disclaimer: Morgan Chemicals is a pharmaceutical raw material trading and distribution company. This API is sourced from DRAP-registered, GMP-certified manufacturing partners. Morgan Chemicals does not manufacture APIs, does not hold DRAP manufacturing registration, and does not sell finished medicines. This product is supplied exclusively to licensed pharmaceutical companies, CMOs, and research facilities in Pakistan — not for individual or consumer sale.